TSHA Taysha Gene Therapies Inc.
Health Care, filed as TAYSHA GENE THERAPIES INC (COM SHS), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab
In 2026 Q3 Polen Capital Management added to Taysha Gene Therapies, while Palo Alto Investors and Farallon Capital Management trimmed.
Who owns this now
Largest portfolio weights among holders, up to 1.0% (Palo Alto Investors). Not free-float ownership.
Who owns TSHA
Sorted by value, long equity only, as of 2026 Q3.
| History | |||||
|---|---|---|---|---|---|
| Farallon Capital Management | Reduce 0.0% | 2,249,000 | $11M | History | |
| Palo Alto Investors | Reduce −3.9% | 1,337,217 | $6.5M | History | |
| Polen Capital Management | Add +2.9% | 503,379 | $2.5M | History |
Insider trades
Open-market buys and sales by TSHA's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $1.7M sold by 1 insider outside a trading plan
- $3.1M sold by 1 insider under 10b5-1 plans
-
Sukumar Nagendran President and Head of R&DPlanned sale$1.2M 200,000 shares at $6.24 18% of stakeTraded Jul 10 Filed Jul 10
-
Sukumar Nagendran President and Head of R&DPlanned sale$892K 200,000 shares at $4.46 15% of stakeTraded Apr 10 Filed Apr 13
-
Sukumar Nagendran President and Head of R&DPlanned sale$942K 200,000 shares at $4.71 17% of stakeTraded Jan 12 Filed Jan 14
-
Sukumar Nagendran President and Head of R&DSale$1.7M 370,172 shares at $4.58 27% of stakeTraded Nov 28, 2025–Dec 1, 2025 Filed Dec 1, 2025
Also filed in the last 12 months, not counted as buying or selling: 7 stock grants, 7 sales to cover taxes, and 6 option exercises.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 424B5 | Filing Doc | ||
| 8-K | 1.01,8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total current assets | $149.87M | $142.13M | $324.65M |
| Total non-current assets * | $22.86M | $18.23M | $18.67M |
| Total assets | $172.73M | $160.36M | $343.32M |
| Total current liabilities | $36.76M | $26.23M | $26.55M |
| Total non-current liabilities * | $61.04M | $62.61M | $69.83M |
| Total equity | $74.94M | $71.52M | $246.94M |
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon